Crispr Therapeutics Stock News

They're all successful drugmakers with solid growth prospects.

The biotech stock is making gains despite market pressures, but it's still down roughly 71% from its high.

The biotech stock is making gains despite market pressures, but it''s still down roughly 71% from its high.

Gainers: CRISPR Therapeutics AG (CRSP) +26%. Micron Technology, Inc

The biotech stock is making gains despite market pressures, but it's still down roughly 71% from its high.

Intellia's (NTLA) shares decline following the decision of the USPTO, invalidating the patents licensed by Intellia to develop CRISPR-based gene therapies.

These most-shorted stocks have investors seeing red, but there is a silver lining that's playing out on the price chart for today's buyers. The post 3 Ark Invest Most-Shorted Stocks to Buy appeared fi

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $62.43, marking a +0.02% move from the previous day.

In the last trading session, 2.58 million shares of the CRISPR Therapeutics AG (NASDAQ:CRSP) were traded, and its beta was 2.03. Most recently the company’s share price was $60.35, and it changed around $5.15 or 9.33% from the last close, which brings the market valuation of the company to $4.74B. CRSP currently trades at a … Why CRISPR Therapeutics AG (NASDAQ: CRSP) Stock Should Not Be Taken For Granted By Investors In 2022 Read More »

Don't buy Cathie Wood stocks because the market was singing on Wednesday, purchase them because of a much bigger and bullish picture. The post 3 Cathie Wood Stocks to Buy appeared first on InvestorPla

Recent comments from the company's CEO are prompting bullish momentum for the stock.

ZUG, Switzerland and CAMBRIDGE, Mass., March 08, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for

ZUG, Switzerland and CAMBRIDGE, Mass., March 08, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that it will present an e-poster at the American Association for Cancer Research (AACR) 2022 Annual Meeting, taking place April 8-13, 2022, at the Ernest N. Morial Convention Center in New Orleans, Louisiana, and online.

Despite big gains today, the biotech specialist's share price is still down roughly 46% over the past year of trading.

Despite big gains today, the biotech specialist''s share price is still down roughly 46% over the past year of trading.